查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1675766

2025 年至 2033 年肝素市场规模、份额、趋势及预测（按产品、来源、给药方式、应用、最终用户、配销通路和地区划分）

Heparin Market Size, Share, Trends and Forecast by Product, Source, Mode of Administration, Application, End-User, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

2024IMARC Group全球肝素市场规模价值为 74.6 亿美元。北美目前占据市场主导地位，到 2024 年将占据 36% 的显着市场份额。 对心血管疾病有效治疗方案的需求不断增长、主要参与者对研发活动的大量投资、众多外科手术的日益普及以及易患慢性病的老年人口数量的大幅增加是推动市场发展的关键因素。

肝素 (C12H19NO20S3) 是一种广泛使用的抗凝血剂，它是一种抑制血液凝固的物质，因此在各种医疗应用中至关重要。这种药物来自动物组织，给患者服用可以预防静脉、动脉和肺部的血栓。肝素主要由硫酸多醣组成，其特性包括起效迅速，并能与抗凝血酶 III 形成复合物，使凝血酶失去活性。它用于各种医疗情况，例如手术、透析以及深部静脉栓塞和肺栓塞的治疗。肝素透过增强人体的天然抗凝血反应、分解血块并防止新血块的形成发挥作用。

全球市场主要受对心血管疾病有效治疗方案日益增长的需求所推动。同时，多种多样且价格实惠的肝素选择的广泛普及也为市场提供了动力。此外，老龄人口的大幅增加，更容易罹患凝血疾病，这也成为推动市场成长的重要因素。除此之外，需要抗凝血治疗的手术和侵入性手术的数量不断增加，导致产品需求增加。有组织的医疗保健系统的实施进一步推动了市场的发展，该系统需要对血液相关疾病进行适当的管理。除此之外，导致凝血障碍的生活方式相关疾病的流行也推动了市场的发展。其他推动市场发展的因素包括快速的城市化和现代生活方式、向更积极主动的健康管理的文化转变，以及医疗保健提供者、製药公司和研究机构之间的广泛合作。

肝素市场趋势/驱动因素：

慢性病数大幅增加

全球心臟病、癌症和糖尿病等慢性病的增多，使得抗凝血剂，特别是肝素的使用成为人们关注的焦点。这些慢性病常常会导致血栓和血栓形成等继发性併发症，需要使用抗凝血剂来控制和预防这些可能致命的事件。随着生活方式的不断变化，久坐习惯、不良饮食习惯和其他因素导致这些慢性病的增加，从而推动了对有效的血栓管理治疗的需求。此外，医疗从业人员和医疗机构正在推广预防措施，包括对高风险患者的使用。这种抗凝血剂在治疗日益普遍的疾病併发症方面的广泛应用，成为市场扩张的基石，塑造了医疗保健的现有实践和未来趋势。

药物输送系统的技术不断进步

技术创新已成为市场的关键因素。输液帮浦、预充式註射器和标靶输送等药物传递系统的进步确保了抗凝血剂的给药更加准确、有效。这些创新降低了用药过量和副作用的风险，从而提高了患者的安全性和舒适度。此外，随着医疗技术的发展，数位监控与肝素输送的结合可以即时监测患者的反应，从而实现个人化的治疗计划和更高的治疗效果。对该技术的持续研究和投入不仅改善了抗凝血剂的整体使用体验，而且还增强了医疗保健提供者和患者之间的信任。这方面的技术与医学的融合是一个重要的驱动力，引导市场朝着更动态、以病人为中心的方向发展。

不断增加的监管支持和批准

市场扩张受到监管环境的显着影响，涵盖各个政府机构、国际组织和医疗保健机构。严格的监管环境确保肝素产品符合品质、安全和功效标准。这种审查涵盖每个阶段，从研发阶段到上市后监管。新肝素配方和应用的快速审批流程，以及明确的指导方针和支持政策，有助于促进药物的可用性和正确使用。此外，监管支持通常也延伸到研究的财政诱因、政府与製药公司之间的合作以及针对血栓疾病的公众宣传活动。透过创造一个平衡安全与创新的环境，监管支持成为肝素市场强劲成长、建立信任和确保有需要的患者获得最好的照护的重要支柱。

目录

第 1 章：前言

第 2 章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球肝素市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场区隔：按产品
  • 市场区隔：依来源
  • 市场区隔：依管理模式
  • 市场区隔：按应用
  • 市场区隔：按最终用户
  • 市场区隔：按配销通路
  • 市场分布：按地区
  • 市场预测

第六章：市场区隔：依产品

  • 普通肝素
  • 低分子量肝素 (LMWH)
  • 超低分子量肝素 (ULMWH)

第七章：市场区隔：依来源

  • 牛
  • 猪

第 8 章：市场区隔：依管理模式

  • 口服
  • 肠外

第 9 章：市场区隔：按应用

  • 心房颤动和心臟病
  • 中风
  • 深部静脉血栓形成 (DVT)
  • 肺栓塞（PE）
  • 其他的

第 10 章：市场区隔：依最终用户

  • 医院
  • 诊所
  • 家庭护理设置
  • 门诊手术中心
  • 其他的

第 11 章：市场区隔：按配销通路

  • 医院药房
  • 零售药局
  • 药局
  • 线上商店
  • 其他的

第 12 章：市场区隔：按地区

  • 欧洲
  • 北美洲
  • 亚太地区
  • 中东和非洲
  • 拉丁美洲

第 13 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 14 章：价值链分析

第 15 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 16 章：价格分析

第 17 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • GlaxoSmithKline Plc
    • Shenzhen Hepalink Pharmaceutical Co., Ltd
    • Pfizer Inc.
    • LEO Pharma A/S
    • Sanofi SA
    • Dr. Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Aspen Holdings
    • Baxter International Inc.
    • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
    • Sandoz International GmbH
    • Opocrin SpA
    • Sichuan Deebio Pharmaceutical Co., Ltd.
    • Dongying Tiandong Pharmaceutical Co., Ltd.
Product Code: SR112025A1564

The global heparin market size was valued at USD 7.46 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 9.02 Billion by 2033, exhibiting a CAGR of 2.12% during 2025-2033. North America currently dominates the market, holding a significant market share of 36% in 2024. The rising need for effective treatment options for cardiovascular diseases, substantial investments in R&D activities by the key players, the growing prevalence of numerous surgical procedures, and the considerable rise in the number of geriatric population that is susceptible to chronic diseases are the key factors bolstering the market.

Heparin (C12H19NO20S3) is a widely used anticoagulant, a substance that inhibits blood clotting, making it essential in various medical applications. Sourced from animal tissues, this medication is administered to patients to prevent blood clots in veins, arteries, and lungs. Comprising mainly of sulfated polysaccharides, the properties of heparin include a rapid onset of action and the ability to form a complex with antithrombin III, which inactivates clotting enzymes. It's used in various medical situations such as during surgeries, dialysis, and in the treatment of deep vein thrombosis and pulmonary embolisms. Heparin works by enhancing the body's natural anticoagulant response, breaking down clots, and preventing the formation of new ones.

The global market is primarily driven by the increasing need for effective treatment options for cardiovascular diseases. In line with this, the widespread availability of varied and affordable heparin options is also providing an impetus to the market. Moreover, the considerable rise in the aging population, more susceptible to clotting disorders, is acting as a significant growth-inducing factor for the market. In addition to this, the growing number of surgeries and invasive procedures requiring anticoagulation therapy is resulting in higher product demand. The market is further driven by the implementation of organized healthcare systems that necessitate the proper management of blood-related conditions. Apart from this, the prevalence of lifestyle-related diseases that may lead to clotting disorders is propelling the market. Some of the other factors contributing to the market include rapid urbanization and modern lifestyles, the cultural shift towards more proactive health management, and extensive collaboration between healthcare providers, pharmaceutical companies, and research institutions.

Heparin Market Trends/Drivers:

Considerable rise in the number of chronic conditions

The global rise in chronic conditions such as heart disease, cancer, and diabetes has brought the use of anticoagulants, particularly heparin, into sharp focus. These chronic conditions often lead to secondary complications like blood clots and thrombosis, requiring the administration of anticoagulants to manage and prevent these potentially fatal occurrences. As lifestyles continue to evolve, sedentary habits, poor diet, and other factors are contributing to an increase in these chronic conditions, thereby pushing the demand for effective clot management treatments. Furthermore, healthcare practitioners and medical organizations are promoting preventive measures, including use in at-risk patients. This wide-ranging applications of this anticoagulant in managing complications from an increasingly prevalent group of diseases is serving as a cornerstone in the expansion of the market, shaping both current practices and future trends in healthcare.

Continual technological advancements in drug delivery systems

Technological innovation has become a pivotal factor in the market. The advancement in drug delivery systems, such as infusion pumps, prefilled syringes, and targeted delivery, ensures that the anticoagulant can be administered more accurately and effectively. These innovations reduce the risk of overdosage and side effects, thereby enhancing patient safety and comfort. Additionally, as medical technology evolves, the integration of digital monitoring with heparin delivery allows for real-time monitoring of patient response, enabling personalized treatment plans and greater therapeutic efficacy. The continuous research and investment in this technology not only improve the overall usage experience of anticoagulants but also foster trust among healthcare providers and patients. The convergence of technology and medicine in this aspect is a significant driving force, steering the market towards a more dynamic and patient-centric direction.

Growing regulatory support and approvals

The market expansion is significantly impacted by the regulatory landscape, encompassing various government bodies, international organizations, and healthcare authorities. The stringent regulatory environment ensures that heparin products meet quality, safety, and efficacy standards. This scrutiny extends to every stage, from the research and development phase to post-market surveillance. Rapid approval processes for new Heparin formulations and applications, alongside clear guidelines and supportive policies, help facilitate the drug's availability and proper usage. Furthermore, the regulatory support often extends to financial incentives for research, collaboration between governments and pharmaceutical companies, and public awareness campaigns about blood clot disorders. By cultivating an environment that balances safety with innovation, the regulatory support serves as a key pillar in the robust growth of the Heparin market, fostering trust, and ensuring that the best possible care reaches patients in need.

Heparin Industry Segmentation:

Breakup by Product:

  • Unfractionated Heparin
  • Low Molecular Weight Heparin (LMWH)
  • Ultra-Low Molecular Weight Heparin (ULMWH)

Low molecular weight heparin (LMWH) represents the largest market segment

The growing preference for low molecular weight heparin (LMWH) can be attributed to its enhanced bioavailability and prolonged action compared to the unfractionated variant. LMWH offers a more predictable dose-response relationship, reducing the need for frequent monitoring and dose adjustments. Its lower risk of causing heparin-induced thrombocytopenia (HIT) contributes to its favorability in both prophylactic and therapeutic settings. Additionally, LMWH's ease of subcutaneous administration and potential for outpatient care further promote its adoption, aligning with the trend towards patient-centric healthcare.

On the other hand, the unfractionated heparin and ultra-low molecular weight heparin (ULMWH) segments of the market are driven by several factors. These factors include their clinical efficacy in preventing and treating thrombotic conditions, their diverse applications in addressing deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis, and the influence of physician preferences based on patient profiles and medical history.

Breakup by Source:

  • Bovine
  • Porcine

Porcine accounts for the majority of the market share

The utilization of porcine mucosal tissues as the primary product source is driven by the high concentration of precursors in these tissues. Porcine source remains integral to the heparin production process due to its reliability, scalability, and cost-effectiveness. However, the industry's ongoing exploration of alternative sources, driven by concerns over availability and ethical considerations, underscores the importance of diversifying raw material options to ensure a stable supply chain for this critical anticoagulant.

On the other hand, the use of heparin sourced from bovine origins has been historically prominent in medical applications due to its availability and established track record. Also, continual advances in purification processes have addressed concerns related to potential contaminants and allergenic reactions associated with bovine-sourced anticoagulants, which is impelling the segment.

Breakup by Mode of Administration:

  • Oral
  • Parenteral

Oral represents the largest market segment

The development of oral formulations for anticoagulants marks a significant advancement in patient care. The shift from injectable to oral administration stems from the desire to enhance patient compliance, reduce the burden of injections, and facilitate long-term therapy. However, the challenge lies in achieving consistent bioavailability and maintaining predictable anticoagulation effects with oral formulations. Extensive research and clinical trials are being conducted to refine oral anticoagulant drugs, aiming to strike a balance between efficacy, safety, and convenience.

On the other hand, the parenteral mode of administration, involving injections, offers immediate effects that are particularly suitable for acute situations such as stroke and thrombotic events. This mode of administration ensures predictable dosing, which enhances patient safety and treatment efficacy.

Breakup by Application:

  • Atrial Fibrillation & Heart Attack
  • Stroke
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Others

Atrial fibrillation and heart attacks account for the majority of the market share

Atrial fibrillation and heart attacks are pivotal drivers of the demand for various anticoagulants. The increased incidence of these conditions underscores the critical role of timely and effective anticoagulation in preventing thromboembolic events. Atrial fibrillation, characterized by irregular heart rhythms, necessitates ongoing anticoagulant therapy to prevent blood clot formation and potential stroke. Meanwhile, in the context of heart attacks, the product's role as an adjunctive therapy complements other interventions to prevent further clotting and optimize patient outcomes.

On the other hand, the rising prevalence of stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE) drives the demand for effective anticoagulation therapies. The aging global population contributes to a higher incidence of these conditions, emphasizing the need for suitable treatment options.

Breakup by End-User:

  • Hospitals
  • Clinics
  • Homecare Settings
  • Ambulatory Surgical Centers
  • Others

Hospitals represent the largest market segment

Hospitals serve as central hubs for patient care, where the use of heparin spans from surgical procedures to the treatment of thrombotic events for preventing blood clot formation. Hospitals' high patient throughput and critical nature of care emphasize the need for accessible and effective anticoagulation options. As healthcare facilities continue to evolve, optimizing product utilization and management within hospital protocols contributes to patient safety and overall quality of care.

On the other hand, the growing product applications across clinics, homecare settings, and ambulatory surgical centers reflects its versatility in catering to different patient care environments. This is especially convenient for patients, as it allows effective treatment in home-based or ambulatory settings.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Stores
  • Others

Hospital pharmacies account for the majority of the market share

Hospital pharmacies play a pivotal role in the anticoagulant distribution and management within healthcare institutions. Their efficient procurement, storage, and dispensing of pharmaceuticals impact the product availability for clinicians. Additionally, hospital pharmacies facilitate communication between healthcare providers and manufacturers, ensuring timely restocking and adherence to quality standards. An effectively managed distribution channel contributes to seamless patient care and supports hospital staff in delivering appropriate therapies in a timely manner.

On the other hand, the easy product accessibility in retail pharmacies, drug stores, and online stores ensures wider patient access to necessary anticoagulant medications. This availability caters to diverse consumer preferences, allowing some patients to conveniently obtain anticoagulants from their preferred retail or online sources.

Breakup by Region:

  • Europe
  • North America
  • Asia Pacific
  • Middle East and Africa
  • Latin America

North America exhibits a clear dominance, accounting for the largest heparin market share

The report has also provided a comprehensive analysis of all the major regional markets, which include Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share.

The market in the North America region is propelled by the region's high incidence of chronic diseases, notably cardiovascular disorders, deep vein thrombosis, and pulmonary embolism, fuels the demand for heparin as a vital anticoagulant and thromboprophylactic agent.

This demand is further magnified by the increasing proportion of the aging population, a demographic more prone to conditions necessitating anticoagulant treatment. The region's advanced healthcare infrastructure, coupled with the burgeoning number of surgical procedures, including cardiovascular surgeries and orthopedic interventions, fosters a significant need for heparin-based products to mitigate blood clot formation risks.

Improved awareness of thrombotic disorders and enhanced diagnostic techniques contribute to early detection and treatment, amplifying the necessity for product interventions. The stringent regulatory landscape in North America ensures the secure and effective utilization of anticoagulant drugs, including heparin, while ongoing research, collaborative endeavors, and innovations in the field continually refine product efficacy and safety profile. In summation, a dynamic interplay of demographic trends, healthcare infrastructure, medical awareness, regulatory standards, and research advancements collectively stimulate the rising demand for anticoagulant products across various medical domains.

Competitive Landscape:

The leading market players are investing significantly in R&D to develop improved formulations and delivery methods, enhancing the effectiveness and safety of heparin products. These efforts aim to address medical needs more efficiently and reduce potential side effects. To tap into new markets and diversify revenue streams, major manufacturers are expanding their geographic presence by establishing distribution networks, manufacturing facilities, and sales operations in emerging markets. Additionally, they are investing in advanced quality control measures, adherence to Good Manufacturing Practices (GMP), and transparency in their supply chains to maintain customer trust and regulatory approval. The key players are also forming strategic partnerships with research institutions, healthcare providers, and pharmaceutical companies to collectively advance heparin-based treatments.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • GlaxoSmithKline Plc
  • Shenzhen Hepalink Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • LEO Pharma A/S
  • Sanofi S.A.
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Aspen Holdings
  • Baxter International Inc.
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • Sandoz International GmbH
  • Opocrin S.p.A.
  • Sichuan Deebio Pharmaceutical Co., Ltd.
  • Dongying Tiandong Pharmaceutical Co. Ltd.

Key Questions Answered in This Report

  • 1.How big is the heparin market?
  • 2.What is the future outlook of the heparin market?
  • 3.What are the key factors driving the heparin market?
  • 4.Which region accounts for the largest heparin market share?
  • 5.Which are the leading companies in the global heparin market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Heparin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Product
  • 5.5 Market Breakup by Source
  • 5.6 Market Breakup by Mode of Administration
  • 5.7 Market Breakup by Application
  • 5.8 Market Breakup by End-User
  • 5.9 Market Breakup by Distribution Channel
  • 5.10 Market Breakup by Region
  • 5.11 Market Forecast

6 Market Breakup by Product

  • 6.1 Unfractionated Heparin
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Low Molecular Weight Heparin (LMWH)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Ultra-Low Molecular Weight Heparin (ULMWH)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Source

  • 7.1 Bovine
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Porcine
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Mode of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Parenteral
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Atrial Fibrillation & Heart Attack
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Stroke
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Deep Vein Thrombosis (DVT)
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Pulmonary Embolism (PE)
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by End-User

  • 10.1 Hospitals
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Clinics
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Homecare Settings
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Ambulatory Surgical Centers
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Others
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 Market Breakup by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Retail Pharmacies
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Drug Stores
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast
  • 11.4 Online Stores
    • 11.4.1 Market Trends
    • 11.4.2 Market Forecast
  • 11.5 Others
    • 11.5.1 Market Trends
    • 11.5.2 Market Forecast

12 Market Breakup by Region

  • 12.1 Europe
    • 12.1.1 Market Trends
    • 12.1.2 Market Forecast
  • 12.2 North America
    • 12.2.1 Market Trends
    • 12.2.2 Market Forecast
  • 12.3 Asia Pacific
    • 12.3.1 Market Trends
    • 12.3.2 Market Forecast
  • 12.4 Middle East and Africa
    • 12.4.1 Market Trends
    • 12.4.2 Market Forecast
  • 12.5 Latin America
    • 12.5.1 Market Trends
    • 12.5.2 Market Forecast

13 SWOT Analysis

  • 13.1 Overview
  • 13.2 Strengths
  • 13.3 Weaknesses
  • 13.4 Opportunities
  • 13.5 Threats

14 Value Chain Analysis

15 Porter's Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 GlaxoSmithKline Plc
    • 17.3.2 Shenzhen Hepalink Pharmaceutical Co., Ltd
    • 17.3.3 Pfizer Inc.
    • 17.3.4 LEO Pharma A/S
    • 17.3.5 Sanofi S.A.
    • 17.3.6 Dr. Reddy's Laboratories Ltd.
    • 17.3.7 Teva Pharmaceutical Industries Ltd.
    • 17.3.8 Aspen Holdings
    • 17.3.9 Baxter International Inc.
    • 17.3.10 Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
    • 17.3.11 Sandoz International GmbH
    • 17.3.12 Opocrin S.p.A.
    • 17.3.13 Sichuan Deebio Pharmaceutical Co., Ltd.
    • 17.3.14 Dongying Tiandong Pharmaceutical Co., Ltd.

List of Figures

  • Figure 1: Global: Heparin Market: Major Drivers and Challenges
  • Figure 2: Global: Heparin Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Heparin Market: Breakup by Product (in %), 2024
  • Figure 4: Global: Heparin Market: Breakup by Source (in %), 2024
  • Figure 5: Global: Heparin Market: Breakup by Mode of Administration (in %), 2024
  • Figure 6: Global: Heparin Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Heparin Market: Breakup by End-User (in %), 2024
  • Figure 8: Global: Heparin Market: Breakup by Distribution Channel (in %), 2024
  • Figure 9: Global: Heparin Market: Breakup by Region (in %), 2024
  • Figure 10: Global: Heparin Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 11: Global: Heparin Industry: SWOT Analysis
  • Figure 12: Global: Heparin Industry: Value Chain Analysis
  • Figure 13: Global: Heparin Industry: Porter's Five Forces Analysis
  • Figure 14: Global: Heparin (Unfractionated) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Heparin (Unfractionated) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Heparin (Low Molecular Weight) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Heparin (Low Molecular Weight) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Heparin (Ultra-Low Molecular Weight) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Heparin (Ultra-Low Molecular Weight) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Heparin (Bovine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Heparin (Bovine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Heparin (Porcine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Heparin (Porcine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Heparin (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Heparin (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Heparin (Parenteral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Heparin (Parenteral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Heparin (Atrial Fibrillation & Heart Attack) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Heparin (Atrial Fibrillation & Heart Attack) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Heparin (Stroke) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Heparin (Stroke) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Heparin (Deep Vein Thrombosis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Heparin (Deep Vein Thrombosis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Heparin (Pulmonary Embolism) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Heparin (Pulmonary Embolism) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Heparin (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Heparin (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Heparin (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Heparin (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Global: Heparin (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Global: Heparin (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Global: Heparin (Homecare Settings) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Global: Heparin (Homecare Settings) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Global: Heparin (Ambulatory Surgical Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Global: Heparin (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Global: Heparin (Other End-Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Global: Heparin (Other End-Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Global: Heparin Market: Sales through Hospital Pharmacies (in Million USD), 2019 & 2024
  • Figure 49: Global: Heparin Market Forecast: Sales through Hospital Pharmacies (in Million USD), 2025-2033
  • Figure 50: Global: Heparin Market: Sales through Retail Pharmacies (in Million USD), 2019 & 2024
  • Figure 51: Global: Heparin Market Forecast: Sales through Retail Pharmacies (in Million USD), 2025-2033
  • Figure 52: Global: Heparin Market: Sales through Drug Stores (in Million USD), 2019 & 2024
  • Figure 53: Global: Heparin Market Forecast: Sales through Drug Stores (in Million USD), 2025-2033
  • Figure 54: Global: Heparin Market: Sales through Online Stores (in Million USD), 2019 & 2024
  • Figure 55: Global: Heparin Market Forecast: Sales through Online Stores (in Million USD), 2025-2033
  • Figure 56: Global: Heparin Market: Sales through Other Distribution Channels (in Million USD), 2019 & 2024
  • Figure 57: Global: Heparin Market Forecast: Sales through Other Distribution Channels (in Million USD), 2025-2033
  • Figure 58: Europe: Heparin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Europe: Heparin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: North America: Heparin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: North America: Heparin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Asia Pacific: Heparin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Asia Pacific: Heparin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Middle East and Africa: Heparin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Middle East and Africa: Heparin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Latin America: Heparin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Latin America: Heparin Market Forecast: Sales Value (in Million USD), 2025-2033

List of Tables

  • Table 1: Global: Heparin Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Heparin Market Forecast: Breakup by Product (in Million USD), 2025-2033
  • Table 3: Global: Heparin Market Forecast: Breakup by Source (in Million USD), 2025-2033
  • Table 4: Global: Heparin Market Forecast: Breakup by Mode of Administration (in Million USD), 2025-2033
  • Table 5: Global: Heparin Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 6: Global: Heparin Market Forecast: Breakup by End-User (in Million USD), 2025-2033
  • Table 7: Global: Heparin Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 8: Global: Heparin Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 9: Global: Heparin Market Structure
  • Table 10: Global: Heparin Market: Key Players